[HTML][HTML] The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs

SE Allan, L Passerini, R Bacchetta… - The Journal of …, 2005 - Am Soc Clin Investig
SE Allan, L Passerini, R Bacchetta, N Crellin, M Dai, PC Orban, SF Ziegler, MG Roncarolo…
The Journal of clinical investigation, 2005Am Soc Clin Investig
Little is known about the molecules that control the development and function of CD4+
CD25+ Tregs. Recently, it was shown that the transcription factor FOXP3 is necessary and
sufficient for the generation of CD4+ CD25+ Tregs in mice. We investigated the capacity of
FOXP3 to drive the generation of suppressive CD4+ CD25+ Tregs in humans. Surprisingly,
although ectopic expression of FOXP3 in human CD4+ T cells resulted in induction of
hyporesponsiveness and suppression of IL-2 production, it did not lead to acquisition of …
Little is known about the molecules that control the development and function of CD4+CD25+ Tregs. Recently, it was shown that the transcription factor FOXP3 is necessary and sufficient for the generation of CD4+CD25+ Tregs in mice. We investigated the capacity of FOXP3 to drive the generation of suppressive CD4+CD25+ Tregs in humans. Surprisingly, although ectopic expression of FOXP3 in human CD4+ T cells resulted in induction of hyporesponsiveness and suppression of IL-2 production, it did not lead to acquisition of significant suppressor activity in vitro. Similarly, ectopic expression of FOXP3Δ2, an isoform found in human CD4+CD25+ Tregs that lacks exon 2, also failed to induce the development of suppressor T cells. Moreover, when FOXP3 and FOXP3Δ2 were simultaneously overexpressed, although the expression of several Treg-associated cell surface markers was significantly increased, only a modest suppressive activity was induced. These data indicate that in humans, overexpression of FOXP3 alone or together with FOXP3Δ2 is not an effective method to generate potent suppressor T cells in vitro and suggest that factors in addition to FOXP3 are required during the process of activation and/or differentiation for the development of bona fide Tregs.
The Journal of Clinical Investigation